Alvotech (ALVO)
5.19
-0.13
(-2.44%)
USD |
NASDAQ |
Sep 08, 16:00
5.13
-0.06
(-1.16%)
Pre-Market: 08:30
Alvotech Shareholders Equity (Quarterly) : -191.48M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -191.48M |
| March 31, 2026 | -282.31M |
| December 31, 2025 | -284.49M |
| September 30, 2025 | -176.76M |
| June 30, 2025 | -173.33M |
| March 31, 2025 | -302.29M |
| December 31, 2024 | -412.77M |
| September 30, 2024 | -343.71M |
| June 30, 2024 | -605.92M |
| March 31, 2024 | -658.82M |
| December 31, 2023 | -932.49M |
| September 30, 2023 | -660.85M |
| Date | Value |
|---|---|
| June 30, 2023 | -478.54M |
| March 31, 2023 | -655.77M |
| December 31, 2022 | -564.42M |
| September 30, 2022 | -277.23M |
| June 30, 2022 | |
| March 31, 2022 | 228.21M |
| December 31, 2021 | 224.92M |
| September 30, 2021 | 228.87M |
| June 30, 2021 | 227.77M |
| March 31, 2021 | 228.00M |
| December 31, 2020 | 220.93M |
| September 30, 2020 | 242.55M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Teva Pharmaceutical Industries Ltd. | 7.753B |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
| Anika Therapeutics, Inc. | 137.28M |
| BioCryst Pharmaceuticals, Inc. | -454.29M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.587B |
| Total Liabilities (Quarterly) | 1.779B |
| Debt to Equity Ratio | -7.582 |
| Current Ratio | 1.646 |
| Net Debt Paydown Yield | -3.42% |